Paclitaxel and filgrastim for hematopoietic progenitor cell mobilization in patients with hematologic malignancies after failure of a prior mobilization regimen

References

• Attal M, Harousseau J L, Stoppa A M, Sotto J J, Fuzibet J G, Rossi J F, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–97
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau J L, Facon T, Guilhot F, Doyen C, Fuzibet J G, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495–2502
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Reece D E, Barnett M J, Connors J M, Fairey R N, Fay J W, Greer J P, et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1991; 1871–1879, Erratum at J Clin Oncol 1992;9:1871 – 1879
   PubMed Web of Science ®Google Scholar
• Chao N J, Schriber J R, Grimes K, Long G D, Negrin R S, Raimondi C M, et al. Granulocyte colony-stimulating factor “mobilized” peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993; 81: 2031–2035
   PubMed Web of Science ®Google Scholar
• Schmitz N, Linch D C, Dreger P, Goldstone A H, Boogaerts M A, Ferrant A, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353–357
   PubMed Web of Science ®Google Scholar
• To L B, Haylock D N, Simmons P J, Juttner C A. The biology and clinical uses of blood stem cells. Blood 1997; 89: 2233–2258
   PubMed Web of Science ®Google Scholar
• Stiff P J. Management strategies for the hard-to-mobilize patient. Bone Marrow Transplant 1999; 23(Suppl 2)S29–S33
   PubMed Web of Science ®Google Scholar
• Shpall E J, Champlin R, Glaspy J A. Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 1998; 4: 84–92
   PubMedGoogle Scholar
• Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000; 18: 1360–1377
   PubMed Web of Science ®Google Scholar
• Voog E, Le Q H, Philip I, Benetaib B, Michallet M, Fiere D, et al. Autologous transplantation in acute myeloid leukemia: peripheral blood stem cell harvest after mobilization in steady state by granulocyte colony-stimulating factor alone. Ann Hematol 2001; 80: 584–591
   PubMed Web of Science ®Google Scholar
• Shpall E J. The utilization of cytokines in stem cell mobilization strategies. Bone Marrow Transplant 1999; 23(Suppl 2)S13–S19
   PubMed Web of Science ®Google Scholar
• Lonial S, Hicks M, Rosenthal H, Langston A, Redei I, Torre C, et al. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products. Biol Blood Marrow Transplant 2004; 10: 848–857
   PubMed Web of Science ®Google Scholar
• Elfenbein G J, Sackstein R. Primed marrow for autologous and allogeneic transplantation: a review comparing primed marrow to mobilized blood and steady-state marrow. Exp Hematol 2004; 32: 327–339
   PubMed Web of Science ®Google Scholar
• Tsai T, Callander N, Anderson J, Alisna M, Holle L, Craig F, et al. Prospective controlled study using paclitaxel for peripheral blood stem cell (PBSC) in patients with hematologic malignancies and solid tumors. Blood 1999; 94: 342b
   Web of Science ®Google Scholar
• Tsai T, Callander N, Anderson J, Schndider D, Padayao G, Walsh T, et al. Paclitaxel (PTX) vs. cyclophosphamide (CY) for peripheral blood stem cell mobilization in patients with hematologic malignancies. J Clin Oncol 2001; 20: 14a
   Google Scholar
• Miller H J, Leong T, Khandekar J D, Greipp P R, Gertz M A, Kyle R A. Paclitaxel as the initial treatment of multiple myeloma: an Eastern Cooperative Oncology Group Study (E1A93). Am J Clin Oncol 1998; 21: 553–556
   PubMed Web of Science ®Google Scholar
• Younes A, Ayoub J P, Sarris A, Hagemeister F, North L, Pate O, et al. Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial. Br J Haematol 1997; 96: 328–332
   PubMed Web of Science ®Google Scholar
• Schulman K A, Birch R, Zhen B, Pania N, Weaver C H. Effect of CD34(+) cell dose on resource utilization in patients after high-dose chemotherapy with peripheral-blood stem-cell support. J Clin Oncol 1999; 17: 1227
   PubMed Web of Science ®Google Scholar
• Moskowitz C H, Bertino J R, Glassman J R, Hedrick E E, Hunte S, Coady-Lyons N, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3776–3785
   PubMed Web of Science ®Google Scholar
• Zelenetz A D, Hamlin P, Kewalramani T, Yahalom J, Nimer S, Moskowitz C H. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2003; 14(Suppl 1)i5–i10
   PubMed Web of Science ®Google Scholar
• Akhtar S, Tbakhi A, Humaidan H, El Weshi A, Rahal M, Maghfoor I. ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients. Bone Marrow Transplant 2006; 37: 277–282
   PubMed Web of Science ®Google Scholar
• Gojo I, Guo C, Sarkodee-Adoo C, Meisenberg B, Fassas A, Rapoport A P, et al. High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity. Bone Marrow Transplant 2004; 34: 69–76
   PubMed Web of Science ®Google Scholar
• Koc O N, Gerson S L, Cooper B W, Laughlin M, Meyerson H, Kutteh L, et al. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF. J Clin Oncol 2000; 18: 1824–1830
   PubMed Web of Science ®Google Scholar
• Narayanasami U, Kanteti R, Morelli J, Klekar A, Al-Olama A, Keating C, et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001; 98: 2059–2064
   PubMed Web of Science ®Google Scholar
• Dingli D, Nowakowski G S, Dispenzieri A, Lacy M Q, Hayman S, Litzow M R, et al. Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. Clin Lymphoma Myeloma 2006; 6: 384–388
   PubMedGoogle Scholar
• Sirohi B, Powles R, Cavanagh J, Oakervee H, Dyer P, Rintala T, et al. Collection of peripheral blood stem cells in new patients with myeloma receiving minimal or no prior cytoreductive therapy. Hematology 2007; 12: 113–115
   PubMed Web of Science ®Google Scholar
• Flomenberg N, Devine S M, Dipersio J F, Liesveld J L, McCarty J M, Rowley S D, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106: 1867–1874
   PubMed Web of Science ®Google Scholar
• Calandra G, McCarty J, McGuirk J, Barlogie B, Crocker S, Badel K. AMD3100 plus G-CSF mobilizes the majority of non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), and Hodgkin's disease (HD) patients who failed prior mobilization with other regimens. Blood (Suppl.) 2006; 108: 5218a
   Web of Science ®Google Scholar